Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats

B. Stauch Slusher, K. C. Rissolo, K. F. Anzilotti, P. F. Jackson

Research output: Contribution to journalArticlepeer-review

Abstract

It was shown in the present study that three antagonists of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptor, including 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466) and 6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione (YM90K), caused marked reversal of akinesia when administered into the entopeduncular nucleus of rats rendered parkinsonian by bilateral substantia nigra pars compacta lesion. These data suggest that centrally active AMPA antagonists may have therapeutic utility in the treatment of idiopathic Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)145-149
Number of pages5
JournalJournal of Neural Transmission - Parkinson's Disease and Dementia Section
Volume9
Issue number2-3
DOIs
StatePublished - Jun 1995
Externally publishedYes

Keywords

  • 6-hydroxydopamine
  • AMPA receptors
  • GYKI 52466
  • NBQX
  • Parkinson's disease
  • YM90K
  • dopamine
  • glutamate
  • substantia nigra

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats'. Together they form a unique fingerprint.

Cite this